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Results and discussion AGHD patients with MetS 
had higher WC (91.00 ± 8.28 vs 78.01 ± 7.12), BMI 
(24.95 ± 2.91 VS 23.30 ± 2.80), WHR (0.92 ± 0.06 VS 
0.87 ± 0.07), WHtR (0.53 ± 0.06 VS 0.47 ± 0.05), VAI 
[(5.59 (4.02, 7.55) VS 1.69 (0.87, 3.05)] levels in compar-
ison to those without MetS. Meantime WC, BMI, WHR, 
WHtR, VAI was positively correlated to MetS components. 
ROC curve for participants with AGHD showed that VAI 
had the highest SS of 92% (BMI 0.812; WHR 0.706; WHtR 
0.902; VAI 0.920, respectively) for prediction of MetS in 
AGHD. The optimal cutoff values for different adiposity 
markers in predicting MetS were as follows: WC (79.65), 
BMI (23.46); WHR (0.89); WHtR (0.54); VAI (2.29).
Conclusion In conclusion, our study showed all adiposity 
measures of interest present themselves as easy and practi-
cal tools for use in population studies and clinical practice 
for evaluating MetS in AGDH and VAI was identified as 
the best in Chinese AGHD patients among them.
Keywords Visceral adiposity index · Body adiposity 
index · Metabolic syndrome · Adult growth hormone 
deficiency
Introduction
Adult growth hormone deficiency (AGHD) refers to 
decreased secretion of growth hormones in the adults, 
which results from diseases of the pituitary gland or 
from diseases of the hypothalamus. The clinical mani-
festations of AGHD depend upon the cause as well as 
the type and degree of hormonal insufficiency. Increased 
clustering of conventional cardiovascular risk factors 
such as central obesity, insulin resistance and dyslipi-
demia has been demonstrated in patients with AGHD 
Abstract 
Aim Adult growth hormone deficiency (AGHD) refers 
to decreased secretion of growth hormones in the adults, 
which is associated with increased clustering of conven-
tional cardiovascular risk factors such as central obesity, 
insulin resistance and dyslipidemia. Metabolic syndrome 
(MetS), a recognized risk factor of cardiovascluar diseases, 
shares some clinical features. Given that the prevalence of 
MetS is on the rise in patients with AGHD, and that car-
diovascular disease (CVD) is an important cause of mor-
bidity and mortality in that population, the alternative, 
simple, non-invasive methods of assessing MetS among 
this population are needed. This study aims to determine 
the sensitivity of five anthropometric indices [Body mass 
index (BMI), Waist circumference (WC), Waist-to-hip ratio 
(WHR), Waist-to-height ratio (WHtR) and Visceral adipos-
ity index (VAI)] in predicting metabolic syndrome in Chi-
nese population-based patients with adult growth hormone 
deficiency.
Materials and methods A total of 96 Chinese patients 
with adult growth hormone deficiency were included in this 
study. They were compared with equal number of appar-
ently healthy persons with similar characteristics (matched 
with age and gender) to the previous group. Anthropo-
metric measurements including weight, height, serum 
lipids indices, blood pressure (BP), fasting plasma glucose 
(FPG), WC were measured. BMI, WHR, WHtR, and VAI 
were calculated.
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[1]. According to the World Health Organization (WHO) 
or the National Cholesterol Education Program—Third 
Adult Treatment Panel (ATP III), Metabolic syndrome 
(MetS) is increasingly recognized as a distinct entity 
which comprises the following components: central obe-
sity, hyperglycaemia, hypertension and dyslipidaemia 
[2, 3]. It pointed out that the MetS shares clinical fea-
tures with adult growth hormone deficiency such as cen-
tral obesity, insulin resistance and dyslipidemia. One of 
other features common to both conditions is premature 
atherosclerosis and increased mortality from cardiovas-
cular diseases [4, 5].
In addition, MetS is highly prevalent in hypopitui-
tary patients with GHD of adult onset, as a prevalence 
of 43.1% according to the NCEP definition and of 49.1% 
according to the IDF definition was found in a study 
of 2479 hypopituitary patients with adult-onset GH 
deficiency [6]. A study of moderately–severely obese 
individual with AGHD has addressed the possible role 
of GH in the occurrence of MetS. In the study, com-
pared with patients of nomorl growth hormone, AGHD 
patients show a higher prevalence of MetS, suggesting 
AGHD to be an independent factor in the development 
of MetS [7].
These data demonstrate the association between the 
MetS and AGHD, and emphasize the significance of 
both AGHD and MetS as diseases accompanied with an 
adverse cardiovascular risk profile. Apparently, appropri-
ate indices in predicting MetS among patients with adult 
growth hormone deficiency is insufficient to improve this 
adverse cardiovascular risk profile.
AGHD was associated with the development of vis-
ceral obesity [8]. According to several epidemiological 
studies, visceral obesity is the most predictive fat compo-
nent of cardiovascular (CV) disease and events, and vis-
ceral obesity is a central feature of metabolic syndrome 
[9]. Recently, the AlkaMeSy Study Group introduced a 
index, named visceral adiposity index (VAI), which com-
prises simple anthropometric parameters including body 
mass index (BMI), waist circumference (WC) and meta-
bolic parameters [triglycerides (TG) and high-density 
lipoprotein cholesterol (HDL-C)], which was used as a 
marker of both visceral fat dysfunction and MetS [10]. 
Besides, the research of Somma et  al. shows a strong 
relationship between GH axis, VAI and metabolic risk 
in healthy adults [11]. To date, little information is avail-
able regarding the relation between VAI and AGHD. 
The purpose of the present study was to investigate the 
association between VAI and AGHD, and the sensitivity 
of VAI and other traditional adiposity measures such as 
BMI, WC, waist-to-hip ratio (WHR), waist-height ratio 




GH secretion of subjects were evaluated by insulin toler-
ance test, the gold standard for diagnoses of adult GH defi-
ciency [12, 13]. According to the test, subjects with GH 
peak value <5.0 µg/L were diagnosed as AGHD while GH 
peak value <3.0  μg/L were diagnosed as severe AGHD. 
Finally, a total of 96 patients who confirmed diagnosis of 
AGHD with a duration of at least 2 years, who are recruited 
from the Department of Endocrinology of First Affiliated 
Hospital of Chongqing Medical University during Febru-
ary 2009 to October 2014, were enrolled (30 men and 66 
women, aged 46.12 ± 11.32 years). Equal number of appar-
ently healthy persons with similar characteristics (matched 
with age and gender) to the previous group were recruited 
as control group. The control group was also evaluated by 
insulin tolerance test to exclude they are AGHD.
Inclusion criteria: none of the patients had ever received 
GH therapy and all patients had been receiving adequate 
replacement therapy of the rest of pituitary hormones. Hor-
mone levels but GH of all patients was maintained within 
the normal reference range.
The exclusion criteria for entering this study for both 
groups were: (1) current treatments with drugs known to 
interfere with glucose, lipid metabolism or blood pressure; 
(2) presence of previous diagnosis and already known dia-
betes mellitus or hypertension or a history of malignant 
tumor; (3) already treatment with GH; (4) liver and kidney 
functional disorders or mental disorder.
Methods
The present study was approved by the ethics committee of 
the University and adhered to the tenets of the Declaration 
of Helsinki. Additionally, the written informed consents 
were signed by all participants.
All subjects were interviewed by one person. Interview 
questions collected consisted of smoking status, medical 
history, and level of physical activity. All subjects were 
wearing only underwear without shoes when anthropo-
metric measurements were performed. Anthropometric 
measurements included weight, height, WC, total choles-
terol (TC), TG, HDL-c, low-density lipoprotein choles-
terol (LDL-c), blood pressure (BP), fasting plasma glu-
cose (FPG). Body weight was measured to an accuracy of 
±0.2  kg. Height, WC and hip circumferences (HC) were 
measured to minimum recorded unit 0.1 cm.
WHR was calculated as waist circumference divided 
by hip circumference, and WHtR was computed as 
waist circumference divided by height. BMI formula 
is weight in kilograms divided by height in meters 
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squared. VAI was calculated according to the defini-
tion established by Amato and colleagues [10], men: 
VAI = WC∕[39.68 + (1.88 × BMI)] × TG∕1.03×
1.31∕HDL; women: VAI = WC∕[36.58 + (1.89 × BMI)] ×
TG∕0.81 × 1.52∕HDL.
The ATP III guidelines state that the MetS may be diag-
nosed when a person has three or more of five components. 
These components are: central obesity, importantly, the 
ATP III definition includes waist circumference as the meas-
ure of obesity. (Chinese men: waist circumference >90 cm, 
Chinese women: waist circumference >80  cm), an ele-
vated TG level [TG ≥1.7  mmol/l (150  mg/dl)], a reduced 
HDL cholesterol level [men: <1.03  mmol/l (40  mg/dl); 
women: <1.29 mmol/l (50 mg/dl)], elevated blood pressure 
(SBP ≥ 130/DBP ≥ 85 mmHg) and an elevated fasting glu-
cose concentration [FPG ≥ 5.6 mmol/l (100 mg/dl)] [3].
Statistical analysis
Acquired data were analyzed by SPSS19.0 statistical soft-
ware. The significance level adopted was 1% (p < 0.01). 
Variables were represented by mean, standard deviation, 
and frequency. The Kolmogorov–Smirnov test was used 
to assess if the variables followed a normal distribution. 
Before statistical analysis, not normally distributed param-
eters were logarithmically transformed to approximate a 
normal distribution. The Student’s t test for independent 
samples was applied to compare anthropometric and bio-
chemical profiles between groups. Pearson’s Chi-square 
test was used to compare behavioral characteristics and 
assess the difference in prevalence of (components) the 
MS between AGHD and the control group. The Pearson 
correlation tests were conducted to correlate the analyzed 
anthropometric, biochemical, and pressure parameters with 
MetS components. The receiver operating characteristic 
(ROC) curve was constructed and the area below the curves 
was calculated with a 95% confidence interval.
Results
The anthropometric and metabolic parameters of study 
participants are summarized in Table  1. AGHD reported 
smoking more frequently than the control while level of 
physical activity less frequently than the control, but all of 
that are not significantly different. Age, weight and height 
were similar between both groups. There was a significant 
difference between groups for WC, WHR, WHtR, SBP, 
DBP, TG, HDL-c, FPG, FINS, HOMA-IR, and VAI. Those 
are significantly higher in AGHD group, while HDL-c was 
lower in this group (p < 0.01).
Among 96 AGHD group, 52.1% of AGHD patients 
fulfilled the definition for MetS in this study, which is 
higher than the controls (31.3%). Comparison of compo-
nents of the MetS: hypertriglyceridemia [52.1 vs 24.0%, 
(p < 0.001)], hypertension [45.8 vs 26%, (p < 0.001)] and 
abdominal obesity [58.3 vs 36.5%, (p = 0.002)] were signif-
icantly more prevalent in patients compared with controls 
(Fig.  1). Compare anthropometric and biochemical pro-
files between AGHD with MetS and without MetS shown 
in Table  2. No differences were observed for age, height, 
LDL-c between groups. However, in AGHD with MetS 
group, BMI, WC, WHR, WHtR, VAI, TG, SBP, DBP, 
VAI, FPG, FINS, HOMA-IR were significantly increased 
(p < 0.01), while HDL-c were significantly decreased 
(p < 0.01).
Results of the analyses of the association between MetS 
components and insulin resistance with anthropometric adi-
posity indicesare shown in Table 3. WC, BMI and WHtR 
showed significant correlation with all MetS components 
and HOMA-IR among AGHD. There was a strong signifi-
cant correlation between VAI and all MetS components 
except SBP. Meanwhile, WHR was only significantly asso-
ciated with SBP, FPG, HOMA-IR (p < 0.01). Somehow, all 
adiposity measures of interest present themselves associ-
ated with MetS components. Further, the ROC curve for 
participants with AGHD showed the optimal cutoff values 
for different adiposity markers in predicting MetS as fol-
lows: WC: 79.65 cm, BMI: 23.46 kg/m2; WHR: 0.89 cm/
cm; WHtR: 0.54  cm/cm; VAI: 2.29. Among AGHD, we 
found that VAI had the highest SS of 92% (BMI: 0.812; 
WC: 0.888; WHR: 0.706; WHtR: 0.902; VAI: 0.920, 
respectively) for prediction of MetS in Table 4 and Fig. 2.
Table 3 shows the correlations between VAI and meta-
bolic variables. Irrespective of gender, VAI was sig-
nificantly correlated with MetS components except SBP 
(p < 0.05). Then, we further analysis of correlated with 
MetS components by gender (Table  5). The significant 
association of VAI with DBP, FPG (p < 0.01) in females 
and DBP, FPG (p < 0.05) in males existed. While other sig-
nificant association of VAI and TG, HDL-C, HOMA-IR 
existed in both genders (p < 0.01). Even after adjusting the 
age, the association existed.
Discussion
Epidemiological studies have demonstrated that hypopi-
tuitarism without growth hormone replacement therapy is 
associated with an increased risk of cardiovascular events, 
even a high incidence of cardiovascular mortality [14]. So a 
contributory factor to this has been hypothesized to be GH 
deficiency [15, 16]. In our study, observations, showing 
that AGHD patients have many adverse cardiovascular risk 
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profiles, can explain to some extent in the increased cardio-
vascular mortality of AGHD. One of the observations was 
dyslipidemia. Comparing with healthy controls, AGHD 
patients were characterized by increased concentrations 
of TG, LDL-c, and decreased concentrations of HDL-c. 
The adverse lipid profiles are in agreement with previous 
observations shown in AGHD adults [5, 16, 17]. Second, 
we have observed that AGHD has significantly higher BMI, 
WC, VAI, WHR, WHtR than controls. BMI is a measure 
of overall obesity. WC, WHR are used as indicators of 
Table 1  Comparison of clinical 
characteristics in control and 
AGHD
MetS metabolic syndrome, BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, WHtR 
waist-to-height ratio, VAI visceral adiposity index, SBP systolic blood pressure, DBP diastolic blood pres-
sure, FPG fasting serum glucose, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein 
cholesterol, LDL-C low-density lipoprotein cholesterol, FINS fasting insulin, HOMA-IR, homeostasis 
model of assessment for insulin resistence index
Variable AGHD group (n = 96) Control group (n = 96) p value
Patients no (M/F) 30/66 30/66
MetS no. (N) 50 30
Smoking status (%) 32 (33.3) 31 (32.2) 0.878
Leisure time physical activity (%)
 No 40 (41.6) 36 (37.5) 0.679
 Yes, <150 min/week 38 (39.5) 41 (42.7) 0.660
 Yes, ≥150 min/week 18 (18.7) 19 (19.7) 0.855
Age (year) 46.26 ± 11.26 45.64 ± 13.03 0.723
Height (m) 1.60 ± 0.07 1.59 ± 0.07 0.799
Weight (kg) 59.49 ± 10.73 57.20 ± 9.59 0.104
BMI (kg/m2) 23.20 ± 3.38 22.41 ± 2.59 0.072
WC (cm) 85.60 ± 10.14 75.70 ± 9.04 0.000
WHR 0.90 ± 0.07 0.82 ± 0.06 0.000
WHtR 0.53 ± 0.06 0.47 ± 0.05 0.000
SBP (mmHg) 123.81 ± 14.48 115.54 ± 15.23 0.000
DBP (mmHg) 83.30 ± 8.21 75.18 ± 8.29 0.000
TC (mmol/L) 4.76 (4.00, 5.86) 4.66 (4.11, 5.14) 0.000
TG (mmol/L) 1.71 (1.25, 2.57) 1.28 (0.87, 1.94) 0.000
HDL-C (mmol/L) 1.02 (0.83, 1.33) 1.58 (1.31, 2.12) 0.000
LDL-C (mmol/L) 2.99 (2.64, 3.68) 2.37 (2.03, 2.93) 0.000
FPG (mmol/L) 5.50 (4.96, 6.27) 4.68 (4.23, 5.23) 0.000
FINS (mU/ml) 6.43 ± 3.46 4.57 ± 1.80 0.000
HOMA-IR 2.06 (1.97, 2.14) 1.06 (0.81, 1.37) 0.000
VAI 3.47 (1.67, 5.94) 1.05 (0.67, 1.89) 0.000
Fig. 1  The prevalence of 
(components of) the metabolic 
syndrome in patients with 
growth hormone deficiency at 
baseline compared with healthy 
controls
J Endocrinol Invest 
1 3
abdominal obesity. While VAI and WHtR can take into 
account adipose tissue distribution [10, 18–20]. Thus, an 
enlarged WC or VAI could be due to increased abdomi-
nal subcutaneous or visceral adipose depots. Although the 
best adiposity measurement for predicting CVD remains 
controversial, BMI, WC, VAI, WHR and WHtR were cor-
related with the cardio-metabolic risk factors [20]. What 
is more, visceral adiposity itself was a key driver of the 
cardio-metabolic risk [21]. In a word, visceral obesity may 
be one risk of increasing cardiovascular events of AGHD. 
Third, impaired glucose metabolism characterized by insu-
lin resistance and fasting hyperinsulinemia is often highly 
prevalent in AGHD [7]. In our study, we observed the same 
result that HOMA-IR, FINS, FPG are higher in AGHD 
group. Taken together, it has demonstrated that AGHD has 
high risks of cardiovascular events, and three main reasons 
could be considered as visceral obesity, adverse lipid pro-
files and insulin resistance.
The metabolic syndrome—a collection of factors asso-
ciated with increased risk of cardiovascular disease and 
diabetes—is becoming increasingly common. Our study 
has observed that there is a high prevalence of MetS in 
AGHD. Hypertriglyceridemia, hypertension and abdomi-
nal obesity were more prevalent in untreated patients when 
compared with the age-matched controls, resulting in a 
higher prevalence of the MetS in patients (52.0 vs 29.1%, 
respectively). The present findings are consistent with other 
previous results [22]. Some nonsystematic error in report-
ing of smoking history, physical activity of two groups 
has no significant differences, which can have an impact 
on anthropometric and metabolic parameters. AGHD with 
MetS have more unfavorable lipid abnormalities, abdomi-
nal obesity, and insulin resistance than those of non-MetS, 
which is increasing cardiovascular disease risks. It is gen-
erally thought that intervention for the AGHD with MetS 
Table 2  Comparison of 
anthropometric and biochemical 
profiles between AGHD with 
MetS and without MetS
BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, WHtR waist-to-height ratio, VAI 
visceral adiposity index, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting serum 
glucose, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-
density lipoprotein cholesterol, FINS fasting insulin, HOMA-IR homeostasis model of assessment for insu-
lin resistence index
Variable MetS group (n = 50) Non-MetS group (n = 46) p value
Age (year) 47.70 ± 10.61 44.70 ± 11.84 0.193
Height (m) 1.60 ± 0.06 1.59 ± 0.07 0.642
Weight (kg) 64.20 ± 10.96 57.90 ± 9.39 0.079
BMI (kg/m2) 24.95 ± 2.91 23.30 ± 2.80 0.000
WC (cm) 91.00 ± 8.28 78.01 ± 7.12 0.000
WHR 0.92 ± 0.06 0.87 ± 0.07 0.000
WHtR 0.53 ± 0.06 0.47 ± 0.05 0 000
SBP (mmHg) 128.70 ± 15.10 118.50 ± 11.72 0.000
DBP (mmHg) 87.37 ± 6.94 79.28 ± 7.81 0.000
TC (mmol/L) 4.74 (3.76, 6.00) 4.85 (4.17, 5.72) 0.000
TG (mmol/L) 2.39 (1.76, 2.85) 1.30 (1.65, 1.82) 0.000
HDL-C (mmol/L) 0.88 (0.73, 1.02) 1.29 (1.04, 1.66) 0.000
LDL-C (mmol/L) 3.03 (2.70, 3.78) 2.95 (2.39, 3.28) 0.000
FPG (mmol/L) 6.21 (5.60, 6.81) 5.20 (4.67, 5.50) 0.000
FINS 7.43 ± 4.07 4.19 ± 2.93 0.000
HOMA-IR 1.91 ± 1.09 0.99 ± 0.77 0.000
VAI 5.59 (4.02, 7.55) 1.69 (0.87, 3.05) 0.000
Table 3  Correlation between components of MetS and various body 
indices
BMI body mass index, WC waist circumference, WHR waist-to-hip 
ratio, WHtR waist-to-height ratio, VAI visceral adiposity index, SBP 
systolic blood pressure, DBP diastolic blood pressure, FPG fast-
ing serum glucose, TG triglyceride, HDL-C high-density lipoprotein 
cholesterol, HOMA-IR homeostasis model of assessment for insulin 
resistence index
**p < 0.05





0.444** 0.448** 0.199** 0.460** 0.078
DBP 
(mmHg)
0.607** 0.505** 0.296 0.451** 0.286**
TG (mg/dL) 0.517** 0.316** 0.114 0.341** 0.877**
HDL-c (mg/
dL)
−0.502** −0.429** −0.144 −0.391** −0.395**
FPG (mg/dL) 0.671** 0.526** 0.285** 0.515** 0.517**
HOMA-IR 0.436** 0.543** 0.430** 0.469** 0.357**
 J Endocrinol Invest
1 3
is recombinant human growth hormone (rhGH), but this 
is insufficient to normalize some risk factors in patients. 
However, at present there are no approved drugs that can 
reliably reduce all of the metabolic risk factors over the 
long term. Studies reported that during rhGH replace-
ment at a mean dose of 0.5 +/− 0.2  mg/day resulting in 
IGF-I concentrations in the normal age-adjusted reference 
range, the prevalence of (components of) the MetS did not 
change after 2 or 5 years, even 10 years of treatment with 
rhGH [22, 23]. In a study of Profka and his colleagues, 
Table 4  ROC curves and appropriate cutoff of adiposity indexes in 
metabolic syndrome prediction in AGHD
Variables Cutoff Area 95% Confidence interval p values
BMI (kg/m2) 23.45 0.812 (0.728, 0.896) 0.000
WC (cm) 79.65 0.888 (0.827, 0.950) 0.000
WHR 0.89 0.706 (0.599, 0.812) 0.001
WHtR 0.54 0.902 (0.841, 0.962) 0.000
VAI 2.29 0.920 (0.868, 0.971) 0.031
Fig. 2  The ROC analysis of 
adiposity markers in predicting 
MetS in adult growth hormone 
deficiency
Table 5  Correlation between 
VAI and metabolic syndrome 
components
SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting serum glucose, TG triglyceride, 
HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostasis model of assessment for insulin resist-
ance index
* The P values listed are less than or equal to 0.005
** The P values listed are less than or equal to 0.001
SBP DBP FPG TG HDL-C HOMA-IR
Men
 VAI 0.390 0.495* 0.482* 0.763** −0.864 ** 0.583**
 VAI 0.382 0.488* 0.477* 0.765** −0.870** 0.595**
(Age adjusted)
Women
 VAI 0.235 0.496* 0.463* 0.716** −0.569** 0.391**
 VAI 0.215 0.488* 0.462* 0.715** −0.569** 0.384**
(Age adjusted )
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they compare both short- (1 year) and long-term (5 years) 
effects of rhGH in 38 GHD adult patients [19 operated for 
craniopharyngioma (CP) and 19 for non-functioning pitui-
tary adenoma (NFPA)]. The study suggests that CP patients 
are less sensitive to the positive rhGH effects on lipid pro-
file and body composition and more prone to insulin sensi-
tivity worsening than NFPA patients, resulting in increased 
prevalence of MetS in CP only [24]. So there is growing 
interest in finding an easy and practical tool to using in 
population studies and clinical practice for evaluating MetS 
in AGHD. Better risk assessment algorithms are needed 
to quantify MetS in AGHD. More effectively therapeutic 
strategies were needed to reverse or delay progression of 
MetS in AGHD, thereby minimizing problems of increas-
ing cardiovascular disease in this population.
AGHD with MetS is associated with abdominal obesity, 
blood lipid disorders, insulin resistance, and increased risk 
of developing cardiovascular disease. Of those, abdominal 
obesity—the most prevalent manifestation of metabolic 
syndrome—is a marker of dysfunctional adipose tissue, 
and is of central importance in clinical diagnosis [25]. 
Compared with amount of total body fat, the subgroup of 
individuals with a selective excess of intra-abdominal, or 
visceral adipose tissue is substantially higher risk of being 
characterized by insulin resistance and by the features of 
metabolic syndrome [26, 27]. The VAI, based on simple 
anthropometric and metabolic parameters, as a surrogate 
marker of adipose tissue function and distribution indepen-
dently correlated with cardio-metabolic risk in the general 
population [10]. VAI showed a strong association with both 
insulin sensitivity (evaluated with a euglycemic–hyperinsu-
linemic clamp) and visceral adipose tissue (measured with 
magnetic resonance imaging) [10]. Although VAI is asso-
ciated with visceral adipose tissue and cardio-metabolic 
risk, and a strong relationship among GH axis, VAI and 
cardio-metabolic risk has been demonstrated in study of Di 
Somma, an important question has been raised whether VAI 
is a causal factor or a simple marker of MetS in AGHD. 
Meanwhile, BMI, WC, WHR, WHtR have been reported as 
similarly predictive for the presence of MetS in Peruvian 
adults [20]. The result may be different due to degree and 
the prevalence varies on the basis of ethnicity, genetic sus-
ceptibility and geographic location [23]. So, we anlalyse 
VAI, BMI, WC, WHR, WHtR with MetS components in 
Chinese AGHD. We observed WC, BMI, and WHtR were 
significantly correlated with all MetS components among 
AGHD. Despite the significant association of VAI with 
DBP, FPG (p < 0.01) in females and DBP, FPG (p < 0.05) 
in males, there was a significant correlation between VAI 
and MetS components except SBP before and after age and 
gender adjustment. It is no surprise for association between 
VAI and TG or HDL, because TG and HDL are used to cal-
culate VAI, in addition to find WHR was only significantly 
associated with SBP, and FPG. To an extent, the results 
illustrated all of the adiposity indices was associated with 
MetS components although the WHR was the weakest one. 
Our results are generally consistent with some, though not 
all, prior studies [20, 28, 29]. Insulin resistance is the key 
etiologic defect that defines metabolic syndrome [30], we 
find all adiposity indices interested were associated with 
with HOMA-IR. When we adjust age and gender, the asso-
ciation between VAI and HOMA-IR also exists. Accord-
ing to recently defined criteria, the metabolic syndrome is 
prevalent and associated with a greater risk of atheroscle-
rotic cardiovascular disease than any of its individual com-
ponents [29]. In Popa et  al.’s study, CKD prevalence and 
Framingham 10-year CVD risk score were higher in partic-
ipants with unhealthy metabolic profile [31]. So, we further 
compared the ability of adiposity indices to predict MetS, 
and to determine optimal cutoff values for these indices 
in the diagnoses of MetS among AGHD. We investigated 
the ROC curve of multiple adiposity measures in predict-
ing MetS among AGHD. Clearly in Fig. 1, the areas under 
the ROC curve of all adiposity indices were as follows: 
BMI = 0.812; WC = 0.888; WHR = 0.706; WHtR = 0.902; 
VAI = 0.920. In addition, ROC curve showed the optimal 
cutoff values for different adiposity markers in predicting 
MetS were as follows: WC = 79.65  cm, BMI = 23.46  kg/
m2; WHR: 0.89  cm/cm; WHtR: 0.54  cm/cm; VAI: 2.29. 
It could be suggested that BMI, WC, WHR, WHtR and 
VAI are effective indices with efficacy, cost effectiveness 
and simplicity of use to prediction incidence of MetS in 
AGHD. However, the study showed that the best cutoff of 
WC in predicting MetS in GHD patients was 79.65 cm, i.e., 
80  cm. This is a consequence of the definition of MetS, 
because one of the criteria is to have a WC >80  cm. The 
ROC analysis on WC, as a consequence, is useless due to 
collinearity. In conclusion, first, the study illustrated VAI 
was significant between AGHD with MetS group and Non-
MetS group. Second, VAI is the highest area under the 
ROC curve. Taken together, study indicated VAI was much 
superior to anthropometric indicators of obesity among 
BMI, WHR and WHtR for identifying MetS in patients of 
AGHD.
As yet, there are some limitations in our study that 
require emphasis. First, because of such a small number 
of study patients further research should be undertaken in 
larger sample sizes. Second, the composition of the popu-
lation studied also impacts largely on the prevalence of 
differences in ethnicity. As noted by Paniagua et  al. [32], 
heterogeneity in study findings across studies that have 
assessed cardio-metabolic risk factors in relation to indi-
ces of adiposity may be attributable to differences in race/
ethnicity, age, and gender distributions of participants 
across study populations. We only study Asian, thus, cau-
tion should be considered when extrapolating our results 
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to other ethnic groups. What is more, this time, we did 
not take into account the well-known effects of GH on 
metabolic parameters, and evaluate the effect of the rhGH 
replacement therapy in these patients. We will study this 
aspect in future. Finally, we did not analyze the number of 
other pituitary deficits, which is to better understand if the 
duration of hypopituitarism can influence. In a word, fur-
ther research should be undertaken.
In conclusion, the high prevalence of MetS in AGHD, 
which is increased cardiovascular risk factors, emphasized 
the importance of using simple, useful, broadly applica-
ble measures in epidemiologic studies to assess MetS of 
AGHD. Sensitivity of all adiposity indices studied regard-
ing MetS underscores the importance of body fat distribu-
tion in determining overall MetS risk in adult growth hor-
mone deficiency. Although, WC, BMI, WHR, WHtR, VAI 
all present themsefves as easy and practical tools for use 
in population studies and clinical practice to evaluate MetS 
in AGHD, in our population-based study, we demonstrated 
that the VAI ≥2.29 is an indicator (sensitivity and speci-
ficity of 98 and 71%, respectively) to best predict MetS in 
Chinese patients with AGHD.
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